Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer
We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.
Locally Advanced Stage III or IV Thymic Cancer
DRUG: neoadjuvant docetaxel/cisplatin
Complete resection rate, 4-8 weeks later after completion of neoadjuvant chemotherapy
the number of patients with adverse events, from enrollment to 6 months after completion of chemotherapy
We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.